We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced that it entered into a collaboration agreement with HiFiBiO Therapeutics.
Both companies have entered into a research collaboration and license agreement to develop technology, supporting the discovery of neoantigen-reactive T-cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors.
Per the terms, Kite, which was acquired by Gilead in 2017, will adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will enable in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies.
HiFiBiO will receive a $10-million upfront payment along with milestone payments. In exchange, Kite will have an exclusive option to license HiFiBiO’s platform to screen T-cell repertoires and identify TCRs for use in TCR engineered T-cell therapies with a corresponding payment to HiFiBiO.
Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. (ABBV - Free Report) , the company is looking to HIV and newer avenues to boost its top line.
During the first quarter of 2018, Gilead announced an agreement with Sangamo Therapeutics, Inc. (SGMO - Free Report) to use Sangamo’s zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
Earlier this month, Gilead announced that it has entered into a strategic collaboration with privately held Precision BioSciences to develop therapies aimed at eliminating hepatitis B virus (HBV) using the latter’s gene editing platform, ARCUS.
Gilead’s stock has gained 13.1% in the year so far against the industry's decline of 2.5%.
We note that Gilead acquired Kite Pharma to foray into the emerging field of cell therapy. Kite is a pioneer in cell therapy, having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), depending on the type of cancer. The approval of lead candidate Yescarta, for the treatment of refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL), is a significant boost for the company.
Meanwhile, Gilead is a dominant player in the HIV market with an impressive portfolio. However, the company will have to generate substantial revenues from its HIV franchise and Yescarta to offset the HCV sales decline. This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline (GSK - Free Report) in the HIV market.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
Image: Bigstock
Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors
Gilead Sciences, Inc. (GILD - Free Report) announced that it entered into a collaboration agreement with HiFiBiO Therapeutics.
Both companies have entered into a research collaboration and license agreement to develop technology, supporting the discovery of neoantigen-reactive T-cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors.
Per the terms, Kite, which was acquired by Gilead in 2017, will adapt HiFiBiO’s proprietary single cell technology platform to create a high throughput approach that will enable in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies.
HiFiBiO will receive a $10-million upfront payment along with milestone payments. In exchange, Kite will have an exclusive option to license HiFiBiO’s platform to screen T-cell repertoires and identify TCRs for use in TCR engineered T-cell therapies with a corresponding payment to HiFiBiO.
Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. (ABBV - Free Report) , the company is looking to HIV and newer avenues to boost its top line.
During the first quarter of 2018, Gilead announced an agreement with Sangamo Therapeutics, Inc. (SGMO - Free Report) to use Sangamo’s zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
Earlier this month, Gilead announced that it has entered into a strategic collaboration with privately held Precision BioSciences to develop therapies aimed at eliminating hepatitis B virus (HBV) using the latter’s gene editing platform, ARCUS.
Gilead’s stock has gained 13.1% in the year so far against the industry's decline of 2.5%.
We note that Gilead acquired Kite Pharma to foray into the emerging field of cell therapy. Kite is a pioneer in cell therapy, having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), depending on the type of cancer. The approval of lead candidate Yescarta, for the treatment of refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL), is a significant boost for the company.
Meanwhile, Gilead is a dominant player in the HIV market with an impressive portfolio. However, the company will have to generate substantial revenues from its HIV franchise and Yescarta to offset the HCV sales decline. This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline (GSK - Free Report) in the HIV market.
Zacks Rank
Gilead carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Best Electric Car Stock? You'll Never Guess It
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>